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The aim of this study was to evaluate the effect of supplementing healthy men with soy isoflavones
on the serum levels of sex hormones implicated in prostate cancer development. A total of 28
Japanese healthy volunteers (18 equol producers and 10 equol non-producers) between 30 and 59
years of age were given soy isoflavones (60mg daily) supplements for 3 months, and the changes in
their sex hormone levels were investigated at the baseline and after administration. The serum and
urine concentrations of daidzein, genistein, and the levels of equol in the fasting blood samples
and 24-h stored urine samples were also measured. All 28 volunteers completed the 3-month
supplementation with isoflavone. No changes in the serum levels of estradiol and total testosterone
were detected after 3-month supplementation. The serum levels of sex hormone-binding globulin
significantly increased, and the serum levels of free testosterone and dihydrotestosterone (DHT)
decreased significantly after 3-month supplementation. Among the 10 equol non-producers, equol
became detectable in the serum of two healthy volunteers after 3-month supplementation. This
study revealed that short-term administration of soy isoflavones stimulated the production of
serum equol and decreased the serum DHT level in Japanese healthy volunteers. These results
suggest the possibility of converting equol non-producers to producers by prolonged and
consistent soy isoflavones consumption.
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Introduction
Epidemiological studies have shown that the incidences
of malignancies, such as prostate cancer, breast cancer
and colon cancer, are commonly high in the Western
Europe and United States of America, but low in the
Asian populations who consume large amounts of soy
bean foods.
1 Soy bean products are rich in isoflavones,
such as genistein and daidzein. Isoflavones have been
suggested as the principal chemical constituents respon-
sible for the potential preventive effect of soy bean
against prostate cancer.
2 Possible mechanisms have been
proposed for the anti-tumor activity of soy isoflavones
against prostate cancer, including estrogen-like effects,
3
prevention of oxidative DNA damage,
4 reduction in
cancer cell proliferation
5 and inhibition of angiogenesis.
6
It has been argued for long whether the lower
incidences of prostate cancer among the Asian people
are because of the inhibitory effects of isoflavones
(contained abundantly in soy beans) and equol (directly
metabolized from daidzein by the intestinal bacterial
microflora) against prostatic carcinogenesis. Equol has a
weak phytoestrogen activity.
7 Especially, equol and iso-
flavones have a binding affinity to estrogen receptor b.
8
In addition, equol can bind to the sex hormone-binding
globulin (SHBG),
9,10 and inhibit the growth of prostate
cells in vitro.
11,12 Therefore, equol can act as an anti-
androgen and inhibit the development of sex hormone-
dependent tumors, such as mammary gland cancer and
prostate cancer.
12 Earlier, we reported that some people
can metabolize daidzein into equol, whereas others
cannot, and showed that the intake quantity of isofla-
vones and the proportions of equol producers differed
significantly among the races and age stratifications.
13
In this intervention study, to elucidate the biological
impact of isoflavones on equol-producing ability and sex
hormonal variation in association with prostate carcino-
genesis, we investigated whether the constant daily
consumption of isoflavone supplements influenced the
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www.nature.com/pcanserum levels of isoflavones, equol and sex hormonal
biomarkers in healthy Japanese men.
Participants and methods
A total of 28 Japanese healthy volunteers (18 equol
producers and 10 equol non-producers), between 30 and
59 years of age were given soy isoflavones (60mg per
day) for 3 months, and the changes in the serum levels of
sex hormones, cholesterol and isoflavones were mea-
sured at the baseline, and at 1 month and 3 months later.
This protocol was designed with reference to earlier
studies.
14–18 This study was conducted to determine the
persistence of diet-induced effects on isoflavone meta-
bolism and disposition. Whether a volunteer is an equol
producer or non-producer was determined as in our
earlier study, in which we conducted a food survey on
the daily intake of soybean isoflavone and measured the
serum concentrations of isoflavone and equol in all
participants.
13 Five tablets of Isofla A (Fuji Oil Co. Ltd,
Osaka, Japan) were administered immediately before
breakfast and dinner twice a day to all volunteers. In
total, 10 tablets per day contained 60mg isoflavone, 2.4g
carbohydrate, 80mg protein, 70mg lipid, 100mg cal-
cium, 60mg magnesium, 30IU vitamin D3, and 3mg
vitamin E. Isoflavone (60mg) consisted of 19.1mg
daidzin, 3.5mg genistin, 10.4mg glycitin, 8.1mg malonyl
daidzin, 2.2mg malonyl genistin, 3.4mg malonyl glyci-
tin, 7.3mg acetyl daidzin, 1.9mg acetyl genistin, 3.6mg
acetyl glycitin, 0.2mg daidzein, 0.1mg genistein and
0.3mg glycitein.
The institutional reviewer board approved this study,
and a written informed consent was obtained from all
the volunteers. Each volunteer was given packages of
Isofla A tablets with a log at the baseline visit. At 1
month and 3 months later, the residual tablets, used
packages and log for counting the residual tablets were
collected from all the volunteers to check the intake
adherence. The intake of isoflavones from daily foods
varied among the volunteers, but they maintained the
same life style, including diet, exercise, work and sleep
patterns, while being enrolled in this study.
Blood samples at 0800 hours before breakfast (after
10-h fasting) and 24-h urine samples were taken at the
baseline, and at 1 month and 3 months after starting
isoflavone administration. For all volunteers, blood
samples were taken before breakfast, and the separated
sera were stored at  201C or lower. Urine was taken for
24h in dark plastic bottles containing 2g ascorbic acid,
and kept in a cool place during storage. The urine was
mixed well and a sample was frozen directly after
measuring the volume. These serum and urine samples
were subsequently transported on dry ice to the
laboratory of SRL Co. Ltd (Tokyo, Japan). The sample
size of all volunteers for detecting the serum isoflavone
concentration was not calculated, but it was regulated by
the feasibility for each investigator.
The concentrations of genistein, daidzein and equol in
the serum and urine samples were measured by
reversed-phase high-performance liquid chromatogra-
phy-multiple reaction ion monitoring mass spectrome-
try.
19 The serum concentrations of cholesterols (total,
high-density lipoproteins and low-density lipoproteins),
estradiol, SHBG, total and free testosterone and dihy-
drotestosterone (DHT) were measured at the same time
points at SRL Co. Ltd.
In addition to comparing the serum concentration of
isoflavones in the two participant groups, we also
compared the participants on the basis of their capability
of equol production. The non-producers were defined as
having a serum equol concentration below the limit of
detection by the present assay system, that is, 0.5ngml
 1.
Statistical analyses were carried out using non-para-
metric Wilcoxon’s test and w
2-test. A P-value of o0.05
was considered as representing a statistically significant
difference.
Results
The demographic characteristics of the healthy volun-
teers are shown in Table 1. Between the equol producers
and the non-producers, there was a significant difference
in age. All 28 volunteers completed the 3-month
isoflavone administration as scheduled. No statistically
significant adverse events were reported by the study
participants. Diarrhea was the most frequently reported
adverse event and occurred in 3 (11%) of the 28
participants. Two participants had diarrhea of grade 1
according to the Common Terminology Criteria for
Adverse Events (v3.0) several times during the con-
secutive 2 days, and one complained of grade 1 diarrhea
once only. No participant discontinued the study regi-
men or withdrew from the study because of these
adverse events. The mean adherence rate was more than
99% during the whole study period. During the 3 months
of Isofla A administration, all participants showed no
marked change in their life styles.
No significant difference was noticed in the total
cholesterol between the mean serum levels at the
baseline and the end of study period. Although the
mean high-density lipoprotein-cholesterol level at 3
months increased significantly when compared with
that of the baseline, the mean low-density lipoprotein-
cholesterol significantly decreased during 3-month iso-
flavone administration (Table 2). No significant changes
in the mean serum levels of estradiol and total
testosterone after 3-month administration were noticed
when compared with the baseline (Table 2). However,
the mean level of SHBG significantly increased after 3
months of isoflavone administration, and the mean
serum levels of free testosterone and DHT decreased
Table 1 Demography of healthy male volunteers
Equol non-
producers
(n¼10)
Equol
producers
(n¼18)
Age (years) 36.7±5.2 43.2±7.8 Po0.05
Height (cm) 170.8±7.3 169.5±6.9 ns
Weight (kg) 64.8±4.1 67.8±3.9 ns
BMI (kgm
 2) 22.2±0.6 23.6±0.7 ns
Former or current smoker 50.0% 55.6% ns
Family history of cancer 40.0% 44.4% ns
Family history of benign
prostatic hyperplasia
30.0% 31.1% ns
Abbreviations: BMI, body mass index; ns, non-significant.
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baseline (Table 2).
The mean serum concentration of isoflavones and
equol at the baseline, and at 1 month and 3 months after
isoflavone administration are shown in Table 3. Genistein
increased more significantly in the urine than in the
serum. Daidzein and equol showed marked increases in
the serum as well as in the urine after 3-month
administration. Two equol non-producers became equol
producers after 3 months of isoflavone administration.
Of these two volunteers, one had serum equol levels of
o0.5ngml
 1, o0.5ngml
 1 and 1.1ngml
 1, whereas the
other had o0.5ngml
 1, 1.1ngml
 1 and 24.1ngml
 1 at
the baseline, 1 month, and 3 months after isoflavone
administration, respectively.
The mean serum levels of cholesterol, SHBG, estra-
diol, testosterone and its metabolites were analyzed
in the equol producers and non-producers (Table 4).
The mean high-density lipoprotein-cholesterol level
significantly increased and the mean low-density lipo-
protein-cholesterol level showed a significant decrease
after 3-month isoflavone administration in the equol
producers. Neither the equol producers nor the non-
producers showed any changes in the mean serum
level of estradiol during the study period. Equol
producers showed a significant increase in the mean
SHBG level and a significant decrease in the mean
DHT level 3 months later. The free testosterone level
showed a significant decrease in the equol produ-
cers, but not in the non-producers, whereas the total
testosterone level showed no significant increase in
both groups.
Discussion
Prostate cancer has recently become an increasingly
important public health issue in Japan. Despite the
extensive studies on the pathogenesis and clinical
behavior of prostate cancer, the etiological origins or
the host-environmental risk factors, which promote its
progression, have not yet been well elucidated.
20 In fact,
the African-American men have the highest morbidity
rates of prostate cancer in the world, whereas the Asian
men natives to their countries, such as the Japanese,
Korean and Chinese, have the lowest rates.
21
However, the incidence of prostate cancer in Japan has
recently increased as the diets and life styles became
westernized. Although latent or clinically insignificant
prostate cancer is detected at a high rate—similar to that
in the American men—in autopsy studies on the Asian
men, the morbidity rate of clinically significant prostate
cancer is 80-fold higher in USA.
22 This suggests that the
same dietary factors may also promote the progression of
latent or microscopic prostate cancer to clinically
significant and metastatic prostate cancer.
23 Some epide-
miological studies indicated that the level of dietary soy
consumption may be linked to a decreased risk of
prostate cancer.
24 The standard intake of isoflavones by
the American men was commonly a couple of milligrams
per day. The ninefold decrease in prostate cancer
mortality among the Japanese men as compared with
that in USA may be attributed, in part, to the high soy
protein content in the Japanese diet.
25
Isofla A tablets are commercially sold in Japan as a
supplement, and the most dominant flavonoid was an
Table 2 Variations of the mean serum levels of cholesterols and sex hormones after isoflavone supplementation
Before supplementation 1 month later 3 months later
Serum cholesterol
Total cholesterol (mg per 100ml) 209.0±35.5 206.7±30.7 204.5±31.7 ns
HDL-cholesterol (mg per 100ml) 55.4±11.8 57.3±10.0 59.8±11.4 Po0.05
LDL-cholesterol (mg per 100ml) 132.2±34.9 127.0±30.9 118.4±30.1 Po0.05
Serum sex hormones
Estradiol (pgml
 1) 25.0±5.6 25.9±5.6 25.2±6.5 ns
Sex hormone-binding globulin (nmoll
 1) 52.2±19.8 47.1±15.1 61.2±19.9 Po0.05
Dihydrotestosterone (ngml
 1) 0.96±0.27 0.78±0.23 0.79±0.23 Po0.05
Free testosterone (pgml
 1) 74.9±3.5 71.8±11.9 70.9±11.2 Po0.05
Total testosterone (pgml
 1) 541.0±125.0 569.0±108.0 576.0±135.0 ns
Abbreviations: HDL, high-density lipoproteins; LDL, low-density lipoproteins; ns, non-significant.
Table 3 Variations of the mean serum and urine levels of genistein, daidzein and equol after isoflavone supplementation
Before supplementation 1 month later 3 months later
Serum isoflavone
Genistein (ngml
 1) 81.7±80.0 108.0±106.4 97.6±97.8 Po0.05
Daidzein (ngml
 1) 40.5±48.4 132.7±109.7 133.8±107.0 Po0.01
Equol (ngml
 1) 21.0±44.8 41.3±69.7 64.7±125.9 Po0.01
Urine isoflavone
Genistein (nmol per day) 23.9±20.5 88.7±66.7 103.1±73.7 Po0.01
Daidzein (nmol per day) 35.8±36.2 41.7±28.7 50.1±41.6 Po0.05
Equol (nmol per day) 12.7±19.8 36.4±40.5 37.9±61.4 Po0.05
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flavonoid glycitin is an isoflavone glycoside present in
foods containing soybean. The metabolite of glycitin
synthesized by intestinal microflora is glycitein, which
scavenges the intracellular reactive oxygen species. The
other ingredients are malonyl or acetyl glycosides and
isoflavone aglycones. Diverse bacterial strains of human
origin have specific b-glucosidase and b-glycuronidase
activity in the metabolism of dietary isoflavones from
glycosides to aglycones. Aglycone and sulfate of
genistein and daidzein have estrogen-like activity and
so does equol.
Genistein reportedly inhibits the growth of androgen-
dependent and androgen-independent prostate cancer
cell lines
26 and inhibits the development of prostate-
related cancers in Wistar rats.
27 The mechanism of action
by which genistein exerts this anti-tumor angiogenesis is
not well understood. Enough scientific data have
accumulated to allow clinical intervention of soy protein
in human trials as an adjuvant supplementation for the
treatment of prostate cancer, but the optimal and
effective doses of soy protein are not yet known. In this
study, we also assessed the effects of the daily consump-
tion of isoflavone supplements on the serum high-
density lipoprotein-cholesterol and low-density lipopro-
tein-cholesterol levels, and measured the isoflavone
concentrations in the blood and urine of healthy men.
Importantly, our results, as well as those of an earlier
study,
14 supported the hypothesis that the continuous
intake of isoflavones is likely to play a promising role in
chemoprevention against cardiovascular disease.
In a recent study, it was found that isoflavones could
increase the production of SHBG in the liver and bind to
biologically active testosterone. Consequently, lowering
the free testosterone levels and its bioavailability to the
target prostate cells should theoretically halt cancer cell
proliferation, inhibit tumor progression and reduce the
tumor volume in accordance with the changes in the
prostate-specific antigen.
16 In our study, the SHBG level
significantly increased, whereas the free testosterone
level and DHT level decreased after 3-month isoflavone
administration as compared with the baseline. This result
is in consensus with several earlier studies and a recent
review on the effects of isoflavone.
11,12,28
On the other hand, there are some limitations of the
product used in our study. The interactions of isofla-
vones and other nutrients included in Isofla A tablets
were not considered. The other ingredients, such as
vitamin D or E, may have some effect on SHBG, DHT or
testosterone levels, although our earlier study showed
that the intake amounts of vitamin D and E were not risk
factors for the development of prostate cancer in
Japanese men.
29 Furthermore, supplementation is usual-
ly a high-dose and unbalanced administration unlike the
physiological condition, and we donot know whether the
supplemental isoflavones behave exactly the same as
isoflavones from the actual food, particularly because the
intestinal microflora variability or genetic differences in
isoflavone metabolism may vary among the individuals
or the races. It is still a question how the food substances
work in the actual food in comparison with their action
in the supplemental form.
Table 4 Variations of the mean serum levels of cholesterols and sex hormones in equol producers and non-producers after isoflavone
supplementation
Before supplementation 1 month later 3 months later
Total cholesterol (mg per 100ml)
Equol producers 209.2±40.1 205.6±30.2 204.1±34.3 ns
Equol non-producers 208.5±27.3 208.7±33.0 205.2±28.3 ns
HDL-cholesterol (mg per 100ml)
Equol producers 53.1±10.3 56.1±10.7 57.7±11.6 Po0.05
Equol non-producers 59.5±13.8 59.5±8.8 63.5±10.4 ns
LDL-cholesterol (mg per 100ml)
Equol producers 134.9±38.4 126.3±31.5 117.1±30.8 Po0.05
Equol non-producers 127.4±28.9 128.7±33.0 120.8±30.3 ns
Estradiol (pgml
 1)
Equol producers 24.7±4.7 25.7±5.1 24.6±5.4 ns
Equol non-producers 25.5±7.2 26.3±6.7 27.0±7.6 ns
Sex hormone-binding globulin (nmoll
 1)
Equol producers 50.1±17.2 45.9±14.9 60.7±22.1 Po0.05
Equol non-producers 56.1±24.3 49.3±15.8 62.0±16.3 ns
Dihydrotestosterone (ngml
 1)
Equol producers 0.93±0.25 0.77±0.24 0.75±0.18 Po0.05
Equol non-producers 1.03±0.32 0.82±0.22 0.86±0.23 ns
Free testosterone (pgml
 1)
Equol producers 74.6±3.8 74.0±4.0 70.1±4.6 Po0.05
Equol non-producers 75.4±3.0 67.8±19.2 73.6±2.6 ns
Total testosterone (pgml
 1)
Equol producers 529.0±119.0 564.0±107.0 541.0±114.0 ns
Equol non-producers 561.0±140.0 578.0±114.0 638.0±153.0 ns
Abbreviations: HDL, high-density lipoproteins; LDL, low-density lipoproteins; ns, non-significant.
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equol or equol itself closely correlated with the lower
incidence of prostate cancer.
30 At 3 months after soy
isoflavone supplementation, serum equol was detected in
two healthy volunteers among the equol non-producers
group. This suggests the possibility of converting equol
non-producers to producers by prolonged and consistent
isoflavones consumption. Moreover, prolonged and con-
sistent isoflavones consumption could potentially delay
the onset of prostate cancer by interfering with carcino-
genesis. A public health initiative now may exist to
identify non-toxic therapies for cancer. Several clinical
trials evaluated the role of various nutritional supplemen-
tations in the treatment of localized prostate cancer. On the
basis of updated scientific evidences, numerous nutritional
strategies could be used for clinical nutrition interventional
trials on the use of individual supplements or dietary
modification versus the incorporation of multiple nutri-
tional strategies. As prostate cancer grows relatively slowly
in comparison with other malignancies, the potential
impact of nutritional intervention may spare patients from
undergoing a variety of toxic treatments for prostate
cancer, and therefore improve their quality of life. The
results of our study warrant further preclinical and clinical
trials focusing on the role of isoflavone in chemopreven-
tion against prostate cancer.
Conclusion
This study revealed that short-term administration of soy
isoflavones to Japanese healthy volunteers increased the
SHBG level, and decreased the free testosterone and
DHT levels. Moreover, equol was detected in the serum
of two healthy volunteers among the equol non-
producers group. These results suggest the possibility
of converting equol non-producers to producers by
prolonged and consistent soy isoflavones consump-
tion, and that a diet based on soy isoflavones will be
useful in preventing prostate cancer development.
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